ReviewCurrent pharmaceutical design2018
Development of Peptide Vaccines in Dengue.
Review in Current pharmaceutical design, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Design of a multi-epitope vaccine against drug-resistant mycobacterium tuberculosis and mycobacterium bovis using reverse vaccinology.Scientific reports · 2025Article
- Review
- Article
- Innovative Immunoinformatics Tools for Enhancing MHC (Major Histocompatibility Complex) Class I Epitope Prediction in Immunoproteomics.Protein and peptide letters · 2025Review
- Current status of the development of dengue vaccines.Vaccine: X · 2025Review
- A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus.Journal of nanobiotechnology · 2024Article
- Design of an Epitope-Based Vaccine Against MERS-CoV.Medicina (Kaunas, Lithuania) · 2024Article
- Rational design of multi-epitope-based vaccine by exploring all dengue virus serotypes proteome: an immunoinformatic approach.Immunologic research · 2024Article
- Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2.Journal of nanobiotechnology · 2024Article
- Genome tuning through HLA and KIR gene clusters impact susceptibility to dengue.Infectious medicine · 2023Review
- Bioinformatics approach for the construction of multiple epitope vaccine against omicron variant of SARS-CoV-2.Scientific reports · 2022Article
- Design of an Epitope-Based Peptide Vaccine Against Dengue Virus Isolate from Eastern Uttar Pradesh, India.International journal of peptide research and therapeutics · 2022Article
- Insight Into Novel Anti-tuberculosis Vaccines by Using Immunoinformatics Approaches.Frontiers in microbiology · 2022Article
- Implementation ofHeliyon · 2021Article
- In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology.Scientific reports · 2021Article
- Immunoinformatics and molecular dynamics approaches: Next generation vaccine design against West Nile virus.PloS one · 2021Article
- Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine.PLoS neglected tropical diseases · 2020Article
- Article
- Landscape and Selection of Vaccine Epitopes in SARS-CoV-2.bioRxiv : the preprint server for biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.